PureTech Health (LON:PRTC) Shares Down 12.4% – Here’s Why

PureTech Health plc (LON:PRTC) shares were down 12.4% on Wednesday . The company traded as low as GBX 100.40 ($1.28) and last traded at GBX 103 ($1.32). Approximately 3,018,245 shares were traded during mid-day trading, an increase of 192% from the average daily volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.50).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 455 ($5.81) price objective on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Stock Down 12.4 %

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The company has a 50-day moving average price of GBX 136.77 and a 200 day moving average price of GBX 148.52. The firm has a market capitalization of £309.39 million, a PE ratio of -4.23 and a beta of 1.02.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.